Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles
Oncocyte Corp (NASDAQ: OCX), a diagnostics technology company, announced its participation in the 17th annual LD Micro Main Event in Los Angeles. CEO Josh Riggs is scheduled to present on Tuesday, October 29th at 2:30 PM PT at The Luxe Sunset Boulevard Hotel. The company's management will also be available for one-on-one meetings with investors.
The LD Micro Main Event XVII will run from October 28th to 30th, featuring approximately 150 companies presenting in half-hour increments and attending private meetings with investors. Registration begins on October 28th at 3:00 PM PT, followed by keynotes and a happy hour. Presentations will run from 8:00 AM to 5:00 PM PT on October 29th and 30th.
Oncocyte Corp (NASDAQ: OCX), un'azienda di tecnologia diagnostica, ha annunciato la sua partecipazione al 17° evento annuale LD Micro Main Event a Los Angeles. Il CEO Josh Riggs è programmato per presentare martedì 29 ottobre alle 14:30 PT presso The Luxe Sunset Boulevard Hotel. La dirigenza dell'azienda sarà inoltre disponibile per incontri individuali con gli investitori.
Il LD Micro Main Event XVII si svolgerà dal 28 al 30 ottobre, con circa 150 aziende che presenteranno in incrementi di mezz'ora e parteciperanno a riunioni private con gli investitori. La registrazione inizia il 28 ottobre alle 15:00 PT, seguita da interventi chiave e un'ora felice. Le presentazioni si svolgeranno dalle 8:00 alle 17:00 PT nei giorni 29 e 30 ottobre.
Oncocyte Corp (NASDAQ: OCX), una empresa de tecnología diagnóstica, anunció su participación en el 17º evento anual LD Micro Main Event en Los Ángeles. El CEO Josh Riggs está programado para presentar el martes 29 de octubre a las 2:30 PM PT en The Luxe Sunset Boulevard Hotel. La dirección de la empresa también estará disponible para reuniones individuales con inversores.
El LD Micro Main Event XVII se llevará a cabo del 28 al 30 de octubre, con aproximadamente 150 empresas presentando en incrementos de media hora y asistiendo a reuniones privadas con inversores. La inscripción comienza el 28 de octubre a las 3:00 PM PT, seguida de discursos magistrales y una hora feliz. Las presentaciones se realizarán de 8:00 AM a 5:00 PM PT los días 29 y 30 de octubre.
Oncocyte Corp (NASDAQ: OCX)는 진단 기술 회사로서 로스앤젤레스에서 열리는 제17회 LD Micro Main Event에 참가한다고 발표했습니다. CEO Josh Riggs는 10월 29일 화요일 오후 2시 30분 PT에 The Luxe Sunset Boulevard Hotel에서 발표할 예정입니다. 회사 경영진은 또한 투자자와의 일대일 미팅에 참석할 수 있습니다.
LD Micro Main Event XVII는 10월 28일부터 30일까지 진행되며, 약 150개 회사가 30분 간격으로 발표하고 투자자와의 비공식 미팅에 참석합니다. 등록은 10월 28일 오후 3시 PT에 시작되며, 이어서 기조 연설과 해피 아워가 진행됩니다. 발표는 10월 29일과 30일 오전 8시부터 오후 5시 PT까지 진행됩니다.
Oncocyte Corp (NASDAQ: OCX), une entreprise de technologie diagnostique, a annoncé sa participation à la 17ème édition annuelle de l’événement LD Micro Main Event à Los Angeles. Le PDG Josh Riggs est prévu pour faire une présentation le mardi 29 octobre à 14h30 PT à The Luxe Sunset Boulevard Hotel. La direction de l’entreprise sera également disponible pour des rencontres individuelles avec les investisseurs.
L’événement LD Micro Main Event XVII se déroulera du 28 au 30 octobre, avec environ 150 entreprises qui présenteront pendant des intervalles de trente minutes et participeront à des réunions privées avec les investisseurs. Les inscriptions commencent le 28 octobre à 15h00 PT, suivies de discours d'ouverture et d'une heure de bonheur. Les présentations auront lieu du 29 au 30 octobre de 8h00 à 17h00 PT.
Oncocyte Corp (NASDAQ: OCX), ein Diagnosetechnologieunternehmen, gab seine Teilnahme am 17. jährlichen LD Micro Main Event in Los Angeles bekannt. CEO Josh Riggs wird am Dienstag, den 29. Oktober um 14:30 Uhr PT im The Luxe Sunset Boulevard Hotel präsentieren. Das Management des Unternehmens wird auch für Einzelgespräche mit Investoren zur Verfügung stehen.
Das LD Micro Main Event XVII findet vom 28. bis 30. Oktober statt und umfasst etwa 150 Unternehmen, die in halbstündigen Präsentationen auftreten und an privaten Meetings mit Investoren teilnehmen. Die Registrierung beginnt am 28. Oktober um 15:00 Uhr PT, gefolgt von Keynotes und einer Happy Hour. Die Präsentationen finden am 29. und 30. Oktober von 8:00 bis 17:00 Uhr PT statt.
- None.
- None.
IRVINE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announced today that CEO Josh Riggs is scheduled to present at the 17th annual Main Event, hosted by LD Micro, on Tuesday, October 29th in Los Angeles.
Oncocyte management will also be available for one-on-one meetings with investors. To schedule a one-on-one meeting, please contact Julie Silber at PCG Advisory (jsilber@pcgadvisory.com) or request a meeting via the LD Micro Conference platform.
Event: LD Micro Main Event XVII
Date: Tuesday, October 29th
Presentation Time: 2:30 PM PT
Location: The Luxe Sunset Boulevard Hotel, Los Angeles
To register to watch the virtual presentation, please click here.
Summary of LD Micro Main Event XVII
The 2024 LD Micro Main Event XVII will run from October 28th to the 30th at the Luxe Sunset Boulevard Hotel in Los Angeles. Registration begins at 3:00 PM PT on October 28th followed by keynotes and happy hour. Presentations will run from 8:00 AM PT to 5:00 PM PT on October 29th and 30th. This three-day event will feature around 150 companies, presenting in half-hour increments, and attending private meetings with investors.
About LD Micro
LD Micro, a wholly owned subsidiary of Freedom US Markets, was founded in 2006 with the sole purpose of being an independent resource in the micro-cap space. Through the LD Micro Index and annual investor conferences, LD has served as an invaluable asset to all those interested in discovering the next generation of great companies. For more information on LD Micro, visit www.ldmicro.com.
About Oncocyte
Oncocyte is a diagnostics technology company. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a clinical blood-based solid organ transplantation monitoring test. GraftAssure™ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit https://oncocyte.com/. For more information about our products, please visit the following web pages:
VitaGraft Kidney™ - https://oncocyte.com/vitagraft-kidney/
VitaGraft Liver™ - https://oncocyte.com/vitagraft-liver/
GraftAssure™ - https://oncocyte.com/graftassure/
DetermaIO™ - https://oncocyte.com/determa-io/
DetermaCNI™ - https://oncocyte.com/determa-cni/
VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation.
CONTACT:
Jeff Ramson
PCG Advisory
(646) 863-6893
jramson@pcgadvisory.com
FAQ
When and where is Oncocyte (OCX) presenting at the LD Micro Main Event XVII?
Who will be presenting for Oncocyte (OCX) at the LD Micro Main Event XVII?
How can investors schedule one-on-one meetings with Oncocyte (OCX) management?
What are the dates for the LD Micro Main Event XVII where Oncocyte (OCX) is participating?
